Demirkan A, Orazakunov E, Savas B, Kuzu MA, Melli M. Enteral glutamine pretreatment does not decrease plasma endotoxin level induced by ischemia-reperfusion injury in rats. World J Gastroenterol 2008; 14(3): 463-468
Corresponding Author of This Article
Arda Demirkan, MD, Ankara University, School of Medicine, Ibni Sina Hospital, Department of Emergency Medicine, Sihhiye 06100, Ankara, Turkey. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 21, 2008; 14(3): 463-468 Published online Jan 21, 2008. doi: 10.3748/wjg.14.463
Enteral glutamine pretreatment does not decrease plasma endotoxin level induced by ischemia-reperfusion injury in rats
Arda Demirkan, Erkin Orazakunov, Berna Savas, M Ayhan Kuzu, Mehmet Melli
Arda Demirkan, Department of Emergency Medicine, Ankara University, School of Medicine, Sihhiye, Ankara, Turkey
Erkin Orazakunov, M Ayhan Kuzu, Department of General Surgery, Ankara University, School of Medicine, Sihhiye, Ankara, Turkey
Berna Savas, Department of Pathology, Ankara University, School of Medicine, Sihhiye, Ankara, Turkey
Mehmet Melli, Department of Pharmacology and Clinical Pharmacology, Ankara University, School of Medicine, Sihhiye, Ankara, Turkey
ORCID number: $[AuthorORCIDs]
Correspondence to: Arda Demirkan, MD, Ankara University, School of Medicine, Ibni Sina Hospital, Department of Emergency Medicine, Sihhiye 06100, Ankara, Turkey. firstname.lastname@example.org
Received: July 8, 2007 Revised: October 30, 2007 Published online: January 21, 2008
AIM: To investigate whether oral glutamine pretreatment prevents impairment of intestinal mucosal integrity during ischemia-reperfusion (I/R) in rats.
METHODS: The study was performed as two series with 40 rats in each. Each series of animals was divided into four groups. The first group was used as a control. Animals in the second group were only pretreated with oral glutamine, 1 g/kg for 4 d. The third group received a normal diet, and underwent intestinal I/R, while the fourth group was pretreated with oral glutamine in the same way, and underwent intestinal I/R. Intestinal mucosal permeability to 51Cr-labeled EDTA was measured in urine in the first series of animals. In the second series, histopathological changes in intestinal tissue and plasma endotoxin levels were evaluated.
RESULTS: Intestinal I/R produced a significant increase in intestinal permeability, plasma endotoxin level and worsened histopathological alterations. After intestinal I/R, permeability was significantly lower in glutamine-treated rats compared to those which received a normal diet. However, no significant change was observed in plasma endotoxin levels or histopathological findings.
CONCLUSION: Although glutamine pretreatment seems to be protective of intestinal integrity, upon I/R injury, such an effect was not observable in the histopathological changes or plasma endotoxin level.
Citation: Demirkan A, Orazakunov E, Savas B, Kuzu MA, Melli M. Enteral glutamine pretreatment does not decrease plasma endotoxin level induced by ischemia-reperfusion injury in rats. World J Gastroenterol 2008; 14(3): 463-468
Intestinal injury as a result of ischemia and subsequent reperfusion plays an important role in a variety of clinical conditions such as shock, and in those undergoing cardiovascular surgery. In these situations, the small intestine may suffer ischemia of varying duration. Intestinal ischemia-reperfusion (I/R) disrupts intestinal mucosal integrity, and causes an increase in intestinal permeability and bacterial translocation. Plasma endotoxin level also increases after I/R. All these have been increasingly recognized as potential causes of multi-system organ failure in critically ill patients[7–9].
Intestinal permeability is assessed non-invasively in vivo by measuring urinary excretion of orally administered test substances. Lactulose, various polymers of polyethylene glycol, 51Cr-labeled EDTA and 99mTc diethylenetriaminepentaacetate are the most commonly used test substances. Test results may be influenced by a change in any of the pre-or post-mucosal factors, apart from intestinal permeability itself. Measurement of intestinal permeability by some test substances may give an idea about some harmful factors such as microorganisms passing through the mucosal barrier, from the intestinal lumen to the systemic circulation. It is thought an increase in plasma endotoxin level is one of the responsible factors which may contribute to the clinical results of intestinal I/R injury. Measurement of plasma endotoxin levels seems to be important in assessing the systemic effect of intestinal I/R.
Glutamine (Gln) is a non-essential amino acid, and the most abundant free amino acid in whole blood and the intracellular amino acid pool. It is an important respiratory fuel, and nucleotide precursor for the gastrointestinal tract. Gln-supplemented parenteral nutrition protects rats against morphological and functional mucosal injury, and improves survival in animals after intestinal I/R. Some other experimental studies have also shown that intraluminal injection of Gln protects the mucosa, and diminishes the accumulation of neutrophils in the lamina propria of the small bowel during I/R. Generation of reactive oxygen intermediates (ROI) during reperfusion is thought to be one of the major causes of intestinal mucosal injury. Gln is also essential for the synthesis of the intrinsic ROI scavenger glutathione. Therefore, this protective action may be due to augmentation of ROI scavenging in intestinal mucosa.
In this study, we aimed to investigate the effects of orogastric Gln pretreatment on intestinal mucosal permeability, plasma endotoxin level and intestinal histopathology during intestinal I/R injury in rats.
MATERIALS AND METHODS
The experiment was performed in female Wistar albino rats weighing 200-230 g. It was approved by the Ankara University Ethical Committee, and was conducted according to the European Community guidelines for the use of experimental animals. Animals were fed with their ordinary diet and allowed to drink water ad libitum. Owing to the time difference between urine collection and blood sampling, the study had to be completed in two series of experiments (Table 1).
Measurement of intestinal permeability by 51Cr-EDTA
Measurement of plasma endotoxin levels and histopathological changes
IV (I/R and Gln)
Induction of intestinal I/R
A rat model of transient mesenteric occlusion was used to obtain intestinal I/R. Rats were anesthetized with ketamine (80 mg/kg, im) and xylazine (10 mg/kg, im). Intestinal I/R was induced by 60 min occlusion, followed by 60 min reperfusion. During the 2 h of the surgical procedure, animals were kept at room temperature, and given intraperitoneal fluid as 0.9% NaCl (10 mL/kg). The superior mesenteric artery (SMA) was exposed through a midline abdominal incision, and both this artery and the collateral branches coming from the celiac axis, and the inferior mesenteric artery were occluded with atraumatic vascular clamps (Vascu-Statt II original No. 1001-532-3; Scanlan International, St Paul, MN, USA) for 1 h, followed by 1 h reperfusion. Existence of pallor and absence of pulsation ensured mesenteric occlusion during the ischemic period. Recovery of pulsation and pink color were controlled in each animal when the clamps were removed. The existence of intestinal I/R in this model was also confirmed in our laboratory by the appearance of pulses at the marginal arteries (direct vision of mesenteric circulation by microscopy), as well as by fluorescein angiography in preliminary experiments.
Measurement of intestinal mucosal permeability
Intestinal mucosal permeability was measured on the basis of urinary radioactivity levels following oral administration of 51Cr-EDTA. 51Cr-EDTA was employed as a well accepted marker of mucosal integrity. After 60 min reperfusion, rats were given 5 &mgr;Ci 51Cr EDTA in 0.5 mL saline solution by the orogastric route. Urine samples were collected in metabolic cages for 6 h following the reperfusion period. During urine collection, animals did not receive any food; however, they were allowed to access tap water. The level of radioactivity in the urine samples of 500 &mgr;L was then determined by counting on a gamma counter (DPC Gambyt CR, Los Angeles. USA). The amount of 51Cr-EDTA excreted in urine during 6 h was calculated as a percentage of the ingested dose.
Measurement of plasma endotoxin level
Plasma endotoxin level was measured by the colorimetric Limulus amebocyte lysate (LAL) test. The test was performed by using the Pyrochrome test kit (Pyroquant Diagnostik, Mörfelden, Germany). All glassware, solutions and surgical instruments used in the experiment were autoclaved at 121°C for 15 min. The non-pyrogenicity of solutions was tested using the LAL test (Charles River Endosafe, Charleston, SC, USA).
Venous blood samples (3-4 mL) were collected using heparin-coated pyrogen-free disposable syringes. Platelet-rich plasma (PRP) was prepared from the blood by centrifugation at 150 g for 10 min. Fifty microliters of PRP was transferred into a polystyrene plastic tube and kept frozen at -80°C until the assay. Frozen PRP samples were kept at room temperature for about 30 min before the assay. Fifty microliters of 0.18 mol/L NaOH was added to 50 &mgr;L PRP, and incubated at 37°C for 5 min. Next, 50 &mgr;L 0.32 mol/L perchloric acid was added, and incubated at 37°C for a further 10 min. To dissolve the formed precipitate, 100 &mgr;L 0.18 mol/L NaOH was added, and vortexed. Twenty-five microliters of the solution was transferred into sterile non-pyrogenic microplates (Pyroquant Diagnostik), and 25 &mgr;L 0.2 mol/L Tris/HCl buffer (pH 8.0) was added to the wells. Finally, 50 &mgr;L pyrochrome test solution was added to all wells, and mixed for 30 s. Plates were incubated at 37°C. Optical density was read at 405 nm. Standard curves from 0.04 to 1.28 EU/mL were used to evaluate the concentration of endotoxin. Results were calculated by using non-linear regression of a four-parameter logistic model.
Histopathological assessment of ileal tissues
After the collection of blood samples, ileal tissue samples, 10 cm proximal to the cecum, were harvested and evaluated for histopathological changes. Sections were stained with hematoxylin and eosin, and were examined by light microscopy by two pathologists in a blinded manner. Mucosal injury was scored on a scale from 0 to 5, as described by Chiu et al.
The SPSS program was used for statistical analysis. Comparison of the various protocols on the changes in intestinal permeability was made by one-way analysis of variance (ANOVA) following a Bonferroni post-hoc test. Changes in plasma endotoxin levels, and intestinal histopathology were determined using a Kruskal-Wallis test following a multiple comparison post-hoc test. Data on changes in intestinal permeability were presented as means ± SEM. Data of plasma endotoxin levels, and intestinal histopathology were presented as medians. P < 0.05 was considered statistically significant.
Effect of Gln pretreatment on intestinal permeability during I/R injury
To investigate the effect of intestinal I/R and Gln pretreatment on intestinal permeability, renal clearance of 51Cr-EDTA was assessed. Statistically significant differences were detected in intestinal permeability in the I/R group when compared to the control group (8.6% ± 1.7% vs 2.4% ± 1.1%, P < 0.001). Gln pretreatment significantly lowered the increased intestinal permeability due to intestinal I/R (8.6% ± 1.7% vs 5.3% ± 1.3%, P < 0.001). There was no statistically significant difference in intestinal permeability between the control and Gln groups (Figure 1).
Figure 1 The effect of enteral Gln pretreatment (1 g/kg per day for four days) on intestinal permeability during I/R injury in rats.
Intestinal I/R was induced by 60 min of occlusion, followed by 60 min of reperfusion. Changes in intestinal permeability were measured by urinary excretion of 51Cr-EDTA after its oral administration in rats. Data are expressed as means ± SEM. bP < 0.001 vs groupI, II and IV; dP < 0.001, vs groupsI, II and III.
Effect of Gln pretreatment on plasma endotoxin level during I/R injury
In the second series of experiments, plasma endotoxin level was evaluated after intestinal I/R injury. There was a statistically significant difference in plasma endotoxin level between the control (group I), and intestinal I/R injury (group III) groups (0.76 EU/mL vs 1.64 EU/mL, P < 0.001). Enteral Gln pretreatment lowered the plasma endotoxin level (group IV), which was increased due to intestinal I/R injury (group III) (1.54 EU/mL vs 1.64 EU/mL, P = 0.48). However, this decrease failed to reach statistical significance. There was no significant difference in plasma endotoxin levels between the control (groupI), and Gln (group II) groups (0.76 EU/mL vs 0.86 EU/mL, P = 0.59) (Figure 2).
Figure 2 The effect of enteral Gln pretreatment (1 g/kg per day for four days) on plasma endotoxin levels during I/R injury in rats.
Intestinal I/R was induced by 60 min of occlusion, followed by 60 min of reperfusion. Changes in plasma endotoxin levels were measured by LAL test. Data are expressed as medians. bP < 0.001 vs groups I and II.
Effect of Gln pretreatment on intestinal histopathological changes during I/R injury
Intestinal histopathological changes were also evaluated in the second series of experiments. There was significant intestinal injury due to intestinal I/R when the control group was compared to the I/R group (0 vs 3, P < 0.001). Gln pretreatment did not significantly decrease intestinal injury compared to the I/R group (3 vs 2, P = 0.389). There was no significant difference in histopathological changes between the control and Gln groups (Figure 3).
Figure 3 The effect of enteral Gln pretreatment (1 g/kg per day for four days) on histopathological changes during I/R injury in rats.
Intestinal I/R was induced by 60 min of occlusion, followed by 60 min of reperfusion. Histopathological changes were scored by the “Chiu” intestinal ischemia scoring system. Data are expressed as medians. bP < 0.001 vs groups I and II.
Ischemia and subsequent reperfusion is one of the major causes of cell injury. The mechanisms of I/R injury are complex, and are likely to differ with respect to the duration of ischemia, the specific tissue involved, and the species studied. The small intestine may experience ischemia and reperfusion during septic shock, hemorrhagic shock or cardio-vascular surgery. These clinical situations can result in some serious postoperative complications such as delay in anastomotic healing. Intestinal mucosa is known to be sensitive to I/R injury. Its basal high rate of oxygen use renders the intestine relatively incapable of increasing oxygen transport in cases of hypoxic stress, and thus is more susceptible to ischemic injury. Intestinal ischemia predisposes the gut to subsequent necrosis. Restoration of blood flow and reintroduction of oxygen after deprivation accelerates tissue injury. Reperfusion of ischemic intestine may lead to more severe functional and morphological changes than the injury produced by ischemia itself. Oxygen free radicals are thought to be generated during the reperfusion phase, with the addition of oxygen to previously ischemic tissues causing the formation of reactive oxygen species.
Intestinal I/R disrupts the functional intestinal mucosal barrier, which results in an increase in mucosal permeability to 51Cr-EDTA. The results of the present study also demonstrated a significant increase in intestinal permeability to 51Cr-EDTA, due to intestinal I/R injury (Figure 1). An increase in mucosal permeability also promotes bacterial translocation. Bacteria colonizing the gastrointestinal tract can translocate from the intestinal lumen to the bloodstream, and this may cause both systemic infection and/or infections in distant organs, such as mesenteric lymph nodes, spleen and liver. Intestinal I/R injury does not only result in bacterial translocation, but also promotes an increase in plasma endotoxin level. Our study also demonstrated a significant increase in plasma endotoxin level parallel to disruption of intestinal tissue in the intestinal I/R group when compared to the control group. Bacterial translocation and increased levels of endotoxin in the circulation may initiate a systemic inflammatory response, and the secretion and activation of inflammatory mediators, including cytokines and metabolites of arachidonic acid. An increase in intestinal permeability, and the deleterious effect of endotoxin in non-steroidal anti-inflammatory drug (NSAID)-induced ulcers has also been observed in experimental NSAID-induced enteropathy. Gut decontamination decreases plasma endotoxin levels, and attenuates the systemic injury in intestinal I/R in rats. A beneficial effect of antibiotics was also observed in NSAID-induced enteropathy.
The results of our study demonstrated that glutamine pretreatment prevented the increase in intestinal permeability during intestinal I/R, which has been reported previously. However, glutamine pretreatment itself did not change the intestinal permeability significantly when compared to that in the control group. It has previously been shown that administration of glutamine-enriched nutritional support protects the bowel from injury due to abdominal irradiation, chemotherapy and sepsis.
Glutamine pretreatment also caused a decrease in plasma endotoxin level, which did not reach statistical significance in our study. Contrary to our result, Wu et al have reported that an increase in plasma endotoxin level due to intestinal I/R can be reduced by Gln-supplemented total parenteral nutrition. However, our study differed from that of Wu et al regarding the dose, route and timing of Gln administration. Furthermore, Gln was delivered in a total parenteral nutrition solution containing various amino acids and lipids in the study of Wu et al. Entrance of 51Cr-EDTA and endotoxin to the systemic circulation from the intestinal lumen may be driven by different mechanisms, which may also explain differential effects of Gln on the above-mentioned parameters. The possibility that colonic epithelial cells contain specific transport systems for endotoxin has been reported. Intestinal I/R disrupted intestinal tissue significantly. Gln pretreatment did not prevent histopathological disruption. It has also been observed that there is no correlation between histopathological alterations and intestinal permeability during recovery after hemorrhagic shock which is accepted as a model of intestinal I/R.
In conclusion, although Gln pretreatment reversed increased intestinal permeability, it did not prevent an increase in plasma endotoxin levels or histopathological alterations in intestinal I/R. Further studies are necessary to clarify the effects of different doses and administration periods of Gln on plasma endotoxin levels and histopathological changes in intestinal I/R.
Impairment of microcirculation during I/R in the gastrointestinal tract may diminish intestinal mucosal integrity and cause an increase in intestinal permeability. Increased plasma endotoxin levels after I/R are a major threat to many surgical patients. Different Gln treatments are known to have protective effects on mucosal integrity in intestinal I/R.
Injury to the intestinal barrier results in an increase in permeability to intraluminal substances. Correlation between morphological alterations and the degree of increased intestinal permeability is uncertain. Recent studies have demonstrated that morphological alterations after intestinal mucosal injury cannot reflect the function of the intestinal barrier.
Innovations and breakthroughs
Recent studies suggest that gastrointestinal epithelial cells contain specific transport systems for lipopolysaccharides.
Intestinal permeability can be measured by many different in vitro and in vivo methods. Endotoxin passing through the intestinal mucosa into the circulation indicates loss of the intestinal barrier function. Measurement of plasma endotoxin level ensures the assessment of real pathogenic factors that arise in the systemic circulation as a result of intestinal mucosal injury.
Bacterial translocation: indigenous bacteria that colonize the gastrointestinal tract can cross the epithelial mucosa to infect distant organs. Under normal conditions, the epithelial lining prevents the escape of these bacteria from the gut lumen. Intestinal permeability: relates to the properties and function of the epithelial barrier that enables unmediated passage of substances through the intestinal mucosa. The use of intestinal permeability tests for screening of intestinal disease and assessment of treatment efficacy, to understand the normal intestinal physiology and pathogenesis of disease, is described and reviewed. There is now a need for research into the basic mechanisms of regulatory control of the intestinal barrier function.
Peer reviewers considered this to be a very interesting paper with a great deal of potential clinical benefit. These basic results may be of value in clinical applications in organ or cellular transplantion.
Supported by a grant from Ankara University Research Fund, Project No. 2004/08/09/185
Stechmiller JK, Treloar D, Allen N. Gut dysfunction in critically ill patients: a review of the literature.Am J Crit Care. 1997;6:204-209.
Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal.Arch Surg. 1970;101:478-483.
Parks DA, Granger DN. Contributions of ischemia and reperfusion to mucosal lesion formation.Am J Physiol. 1986;250:G749-G753.
Vatistas NJ, Nieto JE, Van Hoogmoed L, Gardner I, Snyder JR. Use of an isolated intestinal circuit to evaluate the effect of ischemia and reperfusion on mucosal permeability of the equine jejunum.Vet Surg. 2003;32:52-61.
Langer JC, Sohal SS, Blennerhassett P. Mucosal permeability after subclinical intestinal ischemia-reperfusion injury: an exploration of possible mechanisms.J Pediatr Surg. 1995;30:568-572.
Deitch EA. The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure.Arch Surg. 1990;125:403-404.
Doig CJ, Sutherland LR, Sandham JD, Fick GH, Verhoef M, Meddings JB. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients.Am J Respir Crit Care Med. 1998;158:444-451.
Deitch EA. Bacterial translocation: is it of clinical significance?Gastroenterology. 1990;98:243-244.
Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview.Gastroenterology. 1995;108:1566-1581.
Sorkine P, Szold O, Halpern P, Gutman M, Greemland M, Rudick V, Goldman G. Gut decontamination reduces bowel ischemia-induced lung injury in rats.Chest. 1997;112:491-495.
Ziegler TR, Smith RJ, Byrne TA. Potential role of glutamine supplementation in nutrition support.Clin Nutr. 1993;12 Suppl 1:S82-S90.
Haque SM, Chen K, Usui N, Iiboshi Y, Okuyama H, Masunari A, Cui L, Nezu R, Takagi Y, Okada A. Alanyl-glutamine dipeptide-supplemented parenteral nutrition improves intestinal metabolism and prevents increased permeability in rats.Ann Surg. 1996;223:334-341.
Tazuke Y, Wasa M, Shimizu Y, Wang HS, Okada A. Alanyl-glutamine-supplemented parenteral nutrition prevents intestinal ischemia-reperfusion injury in rats.JPEN J Parenter Enteral Nutr. 2003;27:110-115.
Ikeda S, Zarzaur BL, Johnson CD, Fukatsu K, Kudsk KA. Total parenteral nutrition supplementation with glutamine improves survival after gut ischemia/reperfusion.JPEN J Parenter Enteral Nutr. 2002;26:169-173.
de Aguilar-Nascimento JE, Gurgel Marques C, Carvalho Mariano A, Bicudo Salomao A, de Souza Neves J. Benefits of intraluminal injection of glutamine for intestinal mucosa during ischemia-reperfusion.Eur Surg Res. 2003;35:352-356.
Nilsson UA, Lundgren O, Haglind E, Bylund-Fellenius AC. Radical production during in vivo intestinal ischemia and reperfusion in the cat.Am J Physiol. 1989;257:G409-G414.
Schoenberg MH, Beger HG. Oxygen radicals in intestinal ischemia and reperfusion.Chem Biol Interact. 1990;76:141-161.
Harward TR, Coe D, Souba WW, Klingman N, Seeger JM. Glutamine preserves gut glutathione levels during intestinal ischemia/reperfusion.J Surg Res. 1994;56:351-355.
Jensen JC, Schaefer R, Nwokedi E, Bevans DW 3rd, Baker ML, Pappas AA, Westbrook KC, Klimberg VS. Prevention of chronic radiation enteropathy by dietary glutamine.Ann Surg Oncol. 1994;1:157-163.
Demling RH. Enteral glutamine administration prevents the decrease in cell energy charge potential produced in ileum after a skin burn in the rat.J Burn Care Rehabil. 2000;21:275-279; discussion 274.
Kojima M, Iwakiri R, Wu B, Fujise T, Watanabe K, Lin T, Amemori S, Sakata H, Shimoda R, Oguzu T. Effects of antioxidative agents on apoptosis induced by ischaemia-reperfusion in rat intestinal mucosa.Aliment Pharmacol Ther. 2003;18 Suppl 1:139-145.
Koksoy C, Kuzu MA, Ergun H, Demirpence E, Zulfikaroglu B. Intestinal ischemia and reperfusion impairs vasomotor functions of pulmonary vascular bed.Ann Surg. 2000;231:105-111.
Bjarnason I, Smethurst P, Levi AJ, Peters TJ. Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy.Gut. 1985;26:579-585.
Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation.Gastroenterology. 1997;112:109-117.
Inada K, Endo S, Takahashi K, Suzuki M, Narita T, Yoshida T, Suda H, Komuro T, Yoshida M. Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by the limulus test and clinical application.Microbiol Immunol. 1991;35:303-314.
Conover WJ. Multiple comparison test.2nd ed. New York: John Wiley & Sons 1980; 229-239.
Bulkley GB. Free radicals and other reactive oxygen metabolites: clinical relevance and the therapeutic efficacy of antioxidant therapy.Surgery. 1993;113:479-483.
Tadros T, Traber DL, Heggers JP, Herndon DN. Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis.Ann Surg. 2003;237:101-109.
Chang JX, Chen S, Ma LP, Jiang LY, Chen JW, Chang RM, Wen LQ, Wu W, Jiang ZP, Huang ZT. Functional and morphological changes of the gut barrier during the restitution process after hemorrhagic shock.World J Gastroenterol. 2005;11:5485-5491.
Juel IS, Solligard E, Lyng O, Stromholm T, Tvedt KE, Johnsen H, Jynge P, Saether OD, Aadahl P, Gronbech JE. Intestinal injury after thoracic aortic cross-clamping in the pig.J Surg Res. 2004;117:283-295.
Bjorck M, Troeng T, Bergqvist D. Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case-control study of 2824 operations.Eur J Vasc Endovasc Surg. 1997;13:531-539.
Kologlu M, Yorganci K, Renda N, Sayek I. Effect of local and remote ischemia-reperfusion injury on healing of colonic anastomoses.Surgery. 2000;128:99-104.
Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia.Crit Care Med. 1993;21:1376-1386.
Hammerman C, Goldschmidt D, Caplan MS, Kaplan M, Schimmel MS, Eidelman AI, Branski D, Hochman A. Amelioration of ischemia-reperfusion injury in rat intestine by pentoxifylline-mediated inhibition of xanthine oxidase.J Pediatr Gastroenterol Nutr. 1999;29:69-74.
Ameno H, Tani T, Hanasawa K, Kodama M. New method for the detection of bacterial translocation using intestinal permeability with polyethylene glycol 4000.Eur Surg Res. 2000;32:23-29.
Drewe J, Beglinger C, Fricker G. Effect of ischemia on intestinal permeability of lipopolysaccharides.Eur J Clin Invest. 2001;31:138-144.
Mangino MJ, Anderson CB, Murphy MK, Brunt E, Turk J. Mucosal arachidonate metabolism and intestinal ischemia-reperfusion injury.Am J Physiol. 1989;257:G299-G307.
Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug.J Med Invest. 2004;51:43-51.
Banerjee AK, Peters TJ. Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors.Gut. 1990;31:1358-1364.
Kinouchi T, Kataoka K, Bing SR, Nakayama H, Uejima M, Shimono K, Kuwahara T, Akimoto S, Hiraoka I, Ohnishi Y. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation.Microbiol Immunol. 1998;42:347-355.
Medeiros AC, Chacon DA, Sales VS, Egito ES, Brandao-Neto J, Pinheiro LA, Carvalho MR. Glucan and glutamine reduce bacterial translocation in rats subjected to intestinal ischemia-reperfusion.J Invest Surg. 2006;19:39-46.
Klimberg VS, Salloum RM, Kasper M, Plumley DA, Dolson DJ, Hautamaki RD, Mendenhall WR, Bova FC, Bland KI, Copeland EM 3rd. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation.Arch Surg. 1990;125:1040-1045.
Fox AD, Kripke SA, De Paula J, Berman JM, Settle RG, Rombeau JL. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis.JPEN J Parenter Enteral Nutr. 1988;12:325-331.
Souba WW, Herskowitz K, Klimberg VS, Salloum RM, Plumley DA, Flynn TC, Copeland EM 3rd. The effects of sepsis and endotoxemia on gut glutamine metabolism.Ann Surg. 1990;211:543-549; discussion 549-551.
Tomita M, Ohkubo R, Hayashi M. Lipopolysaccharide transport system across colonic epithelial cells in normal and infective rat.Drug Metab Pharmacokinet. 2004;19:33-40.